Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 28, 2022

Efficacy and Safety of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction by Baseline Glycaemic Status

The Lancet Diabetes & Endocrinology


Additional Info

The Lancet Diabetes & Endocrinology
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial
Lancet Diabetes Endocrinol 2022 Nov 10;[EPub Ahead of Print], SE Inzucchi, BL Claggett, M Vaduganathan, AS Desai, PS Jhund, RA de Boer, AF Hernandez, MN Kosiborod, CSP Lam, F Martinez, SJ Shah, S Verma, Y Han, JF Kerr Saraiva, O Bengtsson, M Petersson, AM Langkilde, JJV McMurray, SD Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading